Every Form 4 that Entera Bio Ltd. (ENTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ENTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTX filings page.
Entera Bio Ltd. reported that director Steven D. Rubin received equity compensation consisting of 19,117 ordinary shares granted in lieu of cash director fees for the first two quarters of 2026 and two stock option awards for 33,368 and 43,405 shares at an exercise price of 1.37 per share. The options, expiring on May 7, 2036, were approved after shareholder authorization and a Form S-8 registration and vest over one- and three-year schedules beginning February 1, 2026, with full acceleration upon a Change in Control. Following the share grant, Rubin directly owns 34,117 ordinary shares.
Malca Yonatan reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that director Yonatan Malca received a grant of 22,815 Ordinary Shares on August 7, 2026. The award, priced at $0.0000 per share, was issued in lieu of cash fees for serving as director for the first and second quarters of 2026. Following this grant, Malca directly holds 100,231 Ordinary Shares. The Board approved the grant on August 5, 2026, subject to effectiveness of a Registration Statement on Form S-8, which occurred on August 7, 2026.
Taitel Haya reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that director Haya Taitel received a board-approved grant of 20,790 ordinary shares on August 7, 2026. The shares were awarded in lieu of cash director fees for the first and second quarters of 2026, after the company filed a Form S-8 registering them. Following this compensation grant, Taitel directly holds 119,269 ordinary shares; the grant carried a reported price of $0.00 per share.
Entera Bio Ltd. director Sean Ellis reported equity compensation awards. He received 20,034 ordinary shares in lieu of cash board fees for the first and second quarters of 2026, after Board approval and a Form S-8 filed on August 7, 2026. He was also granted fully vested options for 40,000 ordinary shares at an exercise price of $1.37 per share, approved earlier in 2026 subject to shareholder approval and the same Form S-8. After these grants, he directly owns 208,132 ordinary shares and holds options for 40,000 shares.
Entera Bio Ltd. reported a grant of stock options to its Chief Financial Officer covering 140,000 ordinary shares at an exercise price of $1.37 per share, expiring on 2036-05-07. The Board approved the grant on May 7, 2026, subject to filing a Registration Statement on Form S-8 for the underlying ordinary shares, which occurred on August 7, 2026. The options vest over three years beginning May 7, 2026, with one third vesting on May 7, 2027 and the remaining two thirds vesting quarterly, subject to full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. granted Chief Operating Officer Hillel Galitzer stock options to buy 200,000 ordinary shares at $1.3700 per share, expiring 2036-05-07. The Board approved the grant on May 7, 2026, contingent on a Form S-8 registration that became effective August 7, 2026. The options vest over three years starting May 7, 2026, with one third vesting on May 7, 2027 and the remaining two-thirds vesting quarterly, subject to full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.
Entera Bio Ltd. granted its Chief of R&D, Gregory Burshtein, 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share. The options expire on May 7, 2036 and vest over three years starting May 7, 2026, with full acceleration upon a Change in Control under the Company’s 2018 Equity Incentive Plan.
Entera Bio Ltd. granted its Chief Executive Officer, Miranda Jayne Toledano, two stock option awards reported as derivative acquisitions on August 7, 2026. One award covers 500,000 ordinary shares at a $1.37 exercise price expiring on May 6, 2036; the other covers 200,000 shares at $2.81 expiring on August 7, 2036.
The 500,000-share grant was approved by the board and shareholders in 2026 and vests over three years beginning May 7, 2026, with one-third vesting on May 7, 2027 and full acceleration upon a Change in Control under the 2018 Equity Incentive Plan. The 200,000-share grant was originally approved in 2022, became effective after a July 2026 financing transaction that funded a Phase 3 trial, and vests over four years starting August 7, 2026, with 25% vesting on the first anniversary and the balance vesting quarterly.
Entera Bio Ltd. director Germano Geno J reported equity compensation. He received 25,014 ordinary shares on August 7, 2026 in lieu of cash director fees for the first two quarters of 2026, raising his direct holdings to 65,014 shares. He was also granted stock options for 50,000 and 43,014 ordinary shares at an exercise price of 1.3700 per share, expiring May 7, 2036 and vesting over one- and three-year schedules starting February 4, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Toledano Miranda Jayne reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that CEO Toledano Miranda Jayne received two grants of stock-settled restricted stock units representing 72,993 and 347,567 ordinary shares on July 14, 2026. The awards were approved by the board on May 7, 2026 and by shareholders on July 14, 2026.
One grant was awarded in lieu of her 2025 annual cash bonus, and the other in lieu of $100,000 of her 2026 base salary. Both RSU grants vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, with full acceleration upon a Change in Control under the company’s 2018 Equity Incentive Plan.
Galitzer Hillel reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that Chief Operating Officer Hillel Galitzer received a grant of 72,993 stock-settled restricted stock units at a stated price of $0.0000 per ordinary share. The Board approved the award on May 7, 2026 in lieu of a cash bonus he was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026. Following this equity award, Galitzer directly holds 163,566 ordinary shares of Entera Bio.
Yaacov-Garbeli Dana reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. granted 58,394 stock-settled restricted stock units tied to its ordinary shares to A2Z Counseling Ltd., an entity associated with Chief Financial Officer Dana Yaacov-Garbeli, as compensation in lieu of a cash bonus. The units vest quarterly over a one-year period that began on May 1, 2026.
Following this award, A2Z Counseling Ltd. held 171,441 ordinary shares indirectly for the reporting person, who owns a 33.33% interest in the entity and has effective voting and disposition control, while disclaiming beneficial ownership beyond any pecuniary interest.
Burshtein Gregory reported acquisition or exercise transactions in this Form 4 filing.
Entera Bio Ltd. reported that its Chief of R&D, Gregory Burshtein, received an equity grant rather than cash. He was awarded 87,591 ordinary shares in the form of stock-settled restricted stock units, approved by the Board on May 7, 2026, in lieu of a cash bonus.
The restricted stock units vest ratably on a quarterly basis over one year, beginning May 1, 2026. After this grant, Burshtein directly owns 189,033 ordinary shares, reflecting routine, compensation-related equity that does not involve any open-market buying or selling.
Entera Bio Ltd. director Germano Geno J reported an open-market purchase of 20,000 Ordinary Shares on March 9, 2026 at a price of 1.30 per share. After this transaction, he directly owns 40,000 Ordinary Shares, doubling his reported direct stake.
Entera Bio Ltd. director Sean Ellis reported an open-market purchase of 10,000 ordinary shares of Entera Bio on March 5, 2026. The weighted average purchase price was $1.23 per share, with individual trades executed between $1.2287 and $1.245. Following this transaction, Ellis directly owns 188,098 ordinary shares of Entera Bio.
Entera Bio Ltd. director Steven D. Rubin reported an open-market purchase of 5,000 ordinary shares at $1.49 per share on February 12, 2026. Following this transaction, he directly beneficially owns 15,000 ordinary shares of Entera Bio.
Entera Bio Ltd. director Haya Taitel reported buying 7,500 ordinary shares on February 10, 2026. The Form 4 shows a purchase at a weighted average price of $1.48 per share, executed through multiple trades between $1.47 and $1.4799, with the holding reported as direct ownership.
Entera Bio Ltd. director transaction: Director Germano J. Geno reported buying 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026. The shares, each with a par value of NIS 0.0000769, were purchased in a direct ownership transaction at a price of $1.49 per share.
Entera Bio director Steven D. Rubin reported a share purchase. On February 9, 2026, he bought 10,000 Ordinary Shares of Entera Bio Ltd. at $1.20 per share.
Following this transaction, Rubin beneficially owns 10,000 Ordinary Shares, all held in direct ownership.
Entera Bio Ltd. director Ellis Sean reported buying 18,000 ordinary shares on February 9, 2026. The purchase was coded as an open-market or private purchase at a weighted average price of $1.24 per share, bringing his directly held stake to 178,098 ordinary shares.
The shares were acquired in multiple trades, with prices ranging from $1.18 to $1.299 per share. Sean is listed as a director of Entera Bio, and the filing shows the ownership as held directly rather than through an intermediary entity.
Entera Bio Ltd. filed details of equity compensation for director Dana Yaacov-Garbeli. On 01/01/2026, the director received 30,157 ordinary shares at a price of $0, bringing total directly held ordinary shares to 77,416. These shares were awarded in lieu of cash fees for services as a director for the 2025 fiscal year.
On the same date, the director was also granted a stock option to buy 33,505 ordinary shares at an exercise price of $1.94 per share, expiring on 01/01/2036. This option represents the Board’s annual option grant to directors and vests ratably on a quarterly basis over a one-year period that began on January 1, 2026. Following these grants, the director beneficially owns 33,505 derivative securities (stock options), all held directly.
Entera Bio Ltd. filed insider transaction details showing equity-based compensation for a company director. On 01/01/2026, the director received 38,294 ordinary shares with par value NIS 0.0000769 per share, reported at a price of $0, in lieu of cash fees for services as a director for the 2025 fiscal year. Following this transaction, the director reported beneficial ownership of 338,454 ordinary shares held directly.
The filing also reports a grant of a stock option on 01/01/2026 to purchase 33,505 ordinary shares at an exercise price of $1.94 per share. These options represent the Board’s annual grant to directors and vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.